Prenetics (NASDAQ: PRE) will report first-quarter 2026 financial results for the period ended March 31, 2026, before market open on May 14, 2026. The company will host an earnings conference call and webcast the same day.
Conference call details: Thursday, May 14, 2026; Time: 8:30 a.m. Eastern Time; Dial-in: 1-877-425-9470; International: 1-201-389-0878; Webcast: PRE Conference Call. An audio replay will be available on the company's investor relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PRE
+1.83%
+1.83%Session close to close
In the May 8 session, PRE gained 1.83%, reflecting a mild positive market reaction.
This announcement sets the Q1 2026 earnings release for May 14, 2026 with a same-day conference call...
Analysis
This announcement sets the Q1 2026 earnings release for May 14, 2026 with a same-day conference call, continuing Prenetics’ regular communication pattern. Historically, similar earnings-date notices led to only a small average move of -0.14%. In parallel, investors may note the active F-3 covering 2,360,416 warrant shares and recent annual report disclosures on net losses, marketing intensity, and Bitcoin-related balance sheet volatility.
Announcement of Q4 and full-year 2025 earnings release and conference call timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior earnings-date scheduling news saw a small negative move, suggesting limited standalone impact from such announcements.
Recent Company History
Over recent months, Prenetics has combined growth initiatives with routine investor communications. Partnership deals for IM8, conference participation, and impact-focused collaborations have shaped the story. For the specific tag "conferences,earnings date", a February 2026 notice about Q4 and full year 2025 results led to a modest -0.14% move, indicating that simple timing announcements have historically prompted only mild trading responses.
Key Terms
warrants, exchange warrants, shelf registration, form 20-f, +3 more
7 terms
warrantsfinancial
"17,352,363 warrants."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
"shares issuable upon exercise of Exchange Warrants. The resale registration covers"
Exchange warrants are tradable securities that give the holder the right, but not the obligation, to swap the warrant for a specific number of a company’s shares (or other securities) at a set price before a deadline. They act like a coupon or ticket that can be turned in for stock: they offer potential upside if the share price rises above the set price, but also create possible dilution and change a company’s share count, so investors watch their terms and expiry closely.
shelf registrationregulatory
"Prenetics Global Ltd Foreign Issuer Shelf Registration"
Shelf registration is when a company gets permission ahead of time to sell new stocks or bonds over a period of time instead of all at once. It matters to investors because it lets a company raise money quickly when needed, but it can also change the value of existing shares if many new ones are sold.
"[20-F] Prenetics Global Ltd Files Annual Report (Foreign Issuer)"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
form f-3regulatory
"existing registration statements on Form F-3 (File Nos. 333-274762, 333-276538"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
form s-8regulatory
"existing registration statements on Form F-3 ... and Form S-8 (File Nos. 333-279019"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
randomized controlled trialmedical
"supported by a 12-week randomized controlled trial."
A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced it will release financial results for the first quarter 2026 ended March 31, 2026 before market open on Thursday, May 14, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
An audio replay of the webcast will be available on the Company’s investor relations website at https://ir.prenetics.com/.
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. IM8’s flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is trusted by NBA Champion and two-time MVP Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka, and F1 driver Ollie Bearman. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within just 11 months and is now sold in more than 40 countries worldwide. IM8 is a subsidiary of Prenetics (NASDAQ: PRE). To learn more, visit www.IM8health.com.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and trusted by NBA superstar Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 40 countries worldwide.
When will Prenetics (PRE) release Q1 2026 results and when is the earnings call?
Prenetics will release Q1 2026 results before market open on May 14, 2026 and hold the earnings call that same day. According to the company, the call is scheduled for May 14, 2026 with a live webcast and an audio replay on the investor relations website.
What time is the Prenetics (PRE) earnings conference call on May 14, 2026?
The conference call is scheduled for 8:30 a.m. Eastern Time on May 14, 2026. According to the company, participants can join via the provided domestic and international dial-in numbers or listen to the live webcast.
How can investors dial in or access the Prenetics (PRE) May 14, 2026 webcast?
Investors can dial 1-877-425-9470 (domestic) or 1-201-389-0878 (international) to join the call. According to the company, the live webcast is labeled 'PRE Conference Call' and will stream on the company's investor relations site.
Will Prenetics (PRE) provide a replay of the Q1 2026 earnings call?
Yes. An audio replay of the webcast will be available on the company's investor relations website after the call. According to the company, the replay can be accessed at https://ir.prenetics.com/ following the live event.
What period do the Prenetics (PRE) Q1 2026 results cover and where will details be posted?
The Q1 2026 results cover the period ended March 31, 2026, and will be released May 14, 2026 before market open. According to the company, financial results and the call webcast will be posted on the investor relations website.
Who should investors contact or where to find more information about Prenetics (PRE) earnings materials?
Investors should consult the Prenetics investor relations website for earnings materials and the webcast link. According to the company, the IR site will host the press release, webcast, and audio replay after the May 14, 2026 event.
